Novel biomarkers for the management of chronic hepatitis B

키워드

참고문헌 (143)

1. "Hepatitis B factsheet"[URL]
2. Inoue T, "Hepatitis B virus and its sexually transmitted infection-an update", Microb Cell, 3, pp.420~437 (2016)
3. Parkin DM, "The global health burden of infection-associated cancers in the year 2002", Int J Cancer, 118, pp.3030~3044 (2006)
4. Lavanchy D, "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
5. Ho SY, "Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma", Sci Rep, 10, pp.3925~ (2020)
6. Lok AS, "Hepatitis B cure : from discovery to regulatory approval", Hepatology, 66, pp.1296~1313 (2017)
7. Glebe D, "The molecular virology of hepatitis B virus", Semin Liver Dis, 33, pp.103~112 (2013)
8. Lopatin U, "Drugs in the pipeline for HBV", Clin Liver Dis, 23, pp.535~555 (2019)
9. Gane EJ, "Future anti-HBV strategies", Liver Int, 37(Suppl 1), pp.40~44 (2017)
10. Inoue T, "The role of hepatitis B core-related antigen", Genes(Basel), 10, pp.357~ (2019)
11. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
12. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
13. Drafting Committee for Hepatitis Management Guidelines, "JSH guidelines for the management of hepatitis B virus infection", Hepatol Res, 44(Suppl S1), pp.1~58 (2014)
14. Velázquez RF, "Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis", Hepatology, 37, pp.520~527 (2003)
15. Tae-Hyung Kim, "Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update", Clinical and Molecular Hepatology, 25(3), pp.245~263 (2019), 대한간학회
16. Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : The Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol Res, 49, pp.1109~1113 (2019)
17. Lin CL, "Perspectives and control of hepatitis B virus infection in Taiwan", J Formos Med Assoc, 114, pp.901~909 (2015)
18. Jun T, "Mac-2binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection", Hepatol Commun, 3, pp.493~503 (2019)
19. Yang HC, "Looking into the crystal ball : biomarkers for outcomes of HBV infection", Hepatol Int, 10, pp.99~101 (2016)
20. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
21. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
22. Kawanaka M, "Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy", Liver Cancer, 3, pp.41~52 (2014)
23. Chuaypen N, "Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy", Clin Microbiol Infect, 24, pp.306~306.e13 (2018)
24. Brouwer WP, "Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up", Clin Gastroenterol Hepatol, 14, pp.1481~1489.e5 (2016)
25. Yeo YH, "Factors associated with rates of HBsAg seroclearance in adults with chronic HBV Infection : a systematic review and meta-analysis", Gastroenterology, 156, pp.635~646.e9 (2019)
26. Chen JD, "Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death", Gastroenterology, 138, pp.1747~1754 (2010)
27. Liu F, "Systematic review with meta-analysis : development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance", Aliment Pharmacol Ther, 43, pp.1253~1261 (2016)
28. Kim GA, "Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients : a need for surveillance", J Hepatol, 62, pp.1092~1099 (2015)
29. Baudi I, "Novel biomarkers of hepatitis B and hepatocellular carcinoma : clinical significance of HBcrAg and M2BPGi", Int J Mol Sci, 21, pp.949~ (2020)
30. Locarnini S, "Molecular genetics of HBV infection", Antivir Ther, 15(Suppl 3), pp.3~14 (2010)
31. Kimura T, "Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal argininerich domain", J Biol Chem, 280, pp.21713~21719 (2005)
32. Hadziyannis E, "Viral biomarkers in chronic HBeAg negative HBV infection", Genes(Basel), 9, pp.469~ (2018)
33. Rokuhara A, "Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment", J Viral Hepat, 10, pp.324~330 (2003)
34. Maasoumy B, "Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D", Clin Microbiol Infect, 21, pp.606.e1~606.e10 (2015)
35. Kimura T, "Sensitive enzyme immunoassay for hepatitis B virus corerelated antigens and their correlation to virus load", J Clin Microbiol, 40, pp.439~445 (2002)
36. Mak LY, "Review article : hepatitis B core-related antigen(HBcrAg) : an emerging marker for chronic hepatitis B virus infection", Aliment Pharmacol Ther, 47, pp.43~54 (2018)
37. Seto WK, "Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B", Clin Microbiol Infect, 20, pp.1173~1180 (2014)
38. Testoni B, "Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients", J Hepatol, 70, pp.615~625 (2019)
39. Riveiro-Barciela M, "Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype", Clin Microbiol Infect, 23, pp.860~867 (2017)
40. Liu YY, "Progression and status of antiviral monitoring in patients with chronic hepatitis B : from HBsAg to HBV RNA", World J Hepatol, 10, pp.603~611 (2018)
41. Hasegawa K, "Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B", Hepatol Res, 49, pp.271~283 (2019)
42. Shimakawa Y, "Hepatitis B core-related antigen : an alternative to hepatitis B virus DNA to assess treatment eligibility in Africa", Clin Infect Dis, 70, pp.1442~1452 (2020)
43. Lai CL, "Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B", J Hepatol, 66, pp.275~281 (2017)
44. Lutgehetmann M, "Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication", Antivir Ther, 13, pp.57~66 (2008)
45. Wong DK, "Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection", J Clin Microbiol, 45, pp.3942~3947 (2007)
46. Wong DK, "Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA", Liver Int, 37, pp.995~1001 (2017)
47. Suzuki F, "Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients", J Med Virol, 81, pp.27~33 (2009)
48. Seto WK, "Evidence of serologic activity in chronic hepatitis B after surface antigen(HBsAg)seroclearance documented by conventional HBsAg assay", Hepatol Int, 7, pp.98~105 (2012)
49. Chuaypen N, "Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B", Liver Int, 36, pp.827~836 (2016)
50. Ma H, "HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon alfa-2b", Chin Med J(Engl), 129, pp.2212~2219 (2016)
51. Wang B, "HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues", J Viral Hepat, 25, pp.886~893 (2018)
52. Wang ML, "Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy", Clin Res Hepatol Gastroenterol, 43, pp.301~309 (2019)
53. Matsumoto A, "Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy", Hepatol Res, 37, pp.661~666 (2007)
54. Shinkai N, "Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection", Hepatol Res, 36, pp.272~276 (2006)
55. Caviglia GP, "Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α", Hepatol Res, 47, pp.747~754 (2017)
56. Jung KS, "Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients", J Gastroenterol, 51, pp.830~839 (2016)
57. Hsu YC, "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk", Aliment Pharmacol Ther, 49, pp.107~115 (2019)
58. Suzuki Y, "HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers", PLoS One, 14, pp.e0212559~ (2019)
59. Ando Y, "Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment", Hepatol Res, 48, pp.E240~E251 (2018)
60. Wong GL, "Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy", World J Gastroenterol, 19, pp.6515~6522 (2013)
61. Hosaka T, "Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues", Aliment Pharmacol Ther, 49, pp.457~471 (2019)
62. Kumada T, "Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients : a propensity score analysis", J Hepatol, 58, pp.427~433 (2013)
63. Honda M, "Hepatitis B virus(HBV)core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma", J Infect Dis, 213, pp.1096~1106 (2016)
64. Tada T, "HBcrAg predicts hepatocellular carcinoma development : an analysis using time-dependent receiver operating characteristics", J Hepatol, 65, pp.48~56 (2016)
65. Tseng TC, "High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load", Gastroenterology, 157, pp.1518~1529.e3 (2019)
66. Cheung KS, "Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy", J Viral Hepat, 24, pp.654~661 (2017)
67. Suzuki Y, "Hepatitis B virus(HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma", Hepatol Res, 49, pp.51~63 (2019)
68. Chen S, "Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients", Clin Chim Acta, 486, pp.237~244 (2018)
69. Kuno A, "A serum"sweet-doughnut"protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)
70. Narimatsu H, "Development of M2BPGi : a novel fibrosis serum glyco-biomarker for chronic hepatitis", cirrhosis diagnostics, 2015, pp.12, 683~693
71. Toshima T, "A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein(WFA(+)-M2BP), for assessing liver fibrosis", J Gastroenterol, 50, pp.76~84 (2015)
72. Sato S, "Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum Wisteria floribunda agglutininpositive Mac-2-binding protein", Int J Mol Sci, 17, pp.2143~ (2016)
73. Zou X, "Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection", Liver Int, 37, pp.35~44 (2017)
74. Abe M, "Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease", J Gastroenterol, 50, pp.776~784 (2015)
75. Yamada N, "Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia", J Gastroenterol, 52, pp.245~252 (2017)
76. Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutininpositive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients", Hepatology, 60, pp.1563~1570 (2014)
77. Chuaypen N, "Serum Wisteria floribunda agglutininpositive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma", Hepatol Res, 48, pp.872~881 (2018)
78. Kim SU, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development", Liver Int, 37, pp.879~887 (2017)
79. Kawanaka M, "Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease", Hepatol Res, 48, pp.521~528 (2018)
80. Yasui Y, "Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus", Hepatol Res, 48, pp.1131~1139 (2018)
81. Mak LY, "Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients", World J Gastroenterol, 25, pp.1398~1408 (2019)
82. Liu J, "Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients", Sci Rep, 7, pp.14352~ (2017)
83. Hsu YC, "Serum M2BPGi level and risk of hepatocellular carcinoma after oral antiviral therapy in patients with chronic hepatitis B", Aliment Pharmacol Ther, 48, pp.1128~1137 (2018)
84. Shinkai N, "High levels of serum Mac-2-binding protein glycosylation isomer(M2BPGi)predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues", J Gastroenterol, 53, pp.883~889 (2018)
85. Cheung KS, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment", Oncotarget, 8, pp.47507~47517 (2017)
86. Hye Soo Kim, "Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection", Clinical and Molecular Hepatology, 26(1), pp.33~44 (2020), 대한간학회
87. Heo JY, "Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus", Medicine(Baltimore), 95, pp.e3328~ (2016)
88. Toyoda H, "Tumor markers for hepatocellular carcinoma : simple and significant predictors of outcome in patients with HCC", Liver Cancer, 4, pp.126~136 (2015)
89. Heimbach JK, "Overview of the updated AASLD guidelines for the management of HCC", Gastroenterol Hepatol(N Y), 13, pp.751~753 (2017)
90. Aghemo A, "Update on HCC management and review of the new EASL guidelines", Gastroenterol Hepatol(N Y), 14, pp.384~386 (2018)
91. Yamamoto K, "Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy", Ann Surg Oncol, 16, pp.2795~2804 (2009)
92. Fedi P, "Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling", J Biol Chem, 274, pp.19465~19472 (1999)
93. Song PP, "Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma", World J Gastroenterol, 22, pp.262~274 (2016)
94. Wang J, "Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma", J Cancer Res Ther, 13, pp.813~816 (2017)
95. Xu Y, "Detection of circulating antibodies to p16 protein-derived peptides in hepatocellular carcinoma", Lab Med (2020)[DOI]
96. Tatarinov IuS, "Detection of embryo-specific alpha-globulin in the blood serum of a patient with primary liver cancer", Vopr Med Khim, 10, pp.90~91 (1964)
97. Linson EA, "More than a tumor marker. . . A potential role for alpha-feto protein in inflammatory bowel disease", Inflamm Bowel Dis, 25, pp.1271~1276 (2019)
98. Ayoub WS, "Current status of hepatocellular carcinoma detection : screening strategies and novel biomarkers", Ther Adv Med Oncol, 11, pp.1758835919869120~ (2019)
99. Reichl P, "Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma : an update for clinicians(review)", Oncol Rep, 36, pp.613~625 (2016)
100. Tsuchiya N, "Biomarkers for the early diagnosis of hepatocellular carcinoma", World J Gastroenterol, 21, pp.10573~10583 (2015)
101. Kudo M, "Alpha-fetoprotein-L3: useful or useless for hepatocellular carcinoma?", Liver Cancer, 2, pp.151~152 (2013)
102. Sterling RK, "Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma", Clin Gastroenterol Hepatol, 7, pp.104~113 (2009)
103. Marrero JA, "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma", Gastroenterology, 137, pp.110~118 (2009)
104. Spangenberg HC, "Serum markers of hepatocellular carcinoma", Semin Liver Dis, 26, pp.385~390 (2006)
105. Li D, "AFP-L3 : a new generation of tumor marker for hepatocellular carcinoma", Clin Chim Acta, 313, pp.15~19 (2001)
106. Choi J, "Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma", Hepatology, 69, pp.1983~1994 (2019)
107. Toyoda H, "Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma", Oncology, 81(Suppl 1), pp.61~65 (2011)
108. Kobayashi M, "Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment preand postoperatively", Hepatol Res, 41, pp.1036~1045 (2011)
109. Setsu T, "Early detection of hepatocellular carcinoma recurrence using the highly sensitive fucosylated fraction of alpha-fetoprotein", Case Rep Gastroenterol, 11, pp.142~147 (2017)
110. Carr BI, "Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gammacarboxy prothrombin in histologically proven hepatocellular carcinoma in the United States", Dig Dis Sci, 52, pp.776~782 (2007)
111. Naraki T, "Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin", Biochim Biophys Acta, 1586, pp.287~298 (2002)
112. Pote N, "Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion", J Hepatol, 62, pp.848~854 (2015)
113. Chen J, "Evaluation of serum des-gamma-carboxy prothrombin for the diagnosis of hepatitis B virus-related hepatocellular carcinoma : a meta-analysis", Dis Markers, 2018, pp.8906023~ (2018)
114. Koike Y, "Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma : a prospective analysis of 227 patients", Cancer, 91, pp.561~569 (2001)
115. Yamashita Y, "Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm", Ann Surg Oncol, 19, pp.2027~2034 (2012)
116. Lee S, "Post-ablation desgamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma", Liver Int, 36, pp.580~587 (2016)
117. Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)
118. Song P, "Biomarkers : evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China", Liver Cancer, 2, pp.31~39 (2013)
119. Caviglia GP, "Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection : a metaanalysis", Scand J Gastroenterol, 53, pp.734~740 (2018)
120. Chen H, "Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma", Cancer Manag Res, 10, pp.1947~1958 (2018)
121. Beale G, "AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease", BMC Cancer, 8, pp.200~ (2008)
122. Caviglia GP, "Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II", Panminerva Med, 59, pp.283~289 (2017)
123. Sassa T, "Clinical utility of simultaneous measurement of serum high-sensitivity des-gammacarboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma", Eur J Gastroenterol Hepatol, 11, pp.1387~1392 (1999)
124. Erdal H, "Combination of DKK1 and AFP improves diagnostic accuracy of hepatocellular carcinoma compared with either marker alone", Turk J Gastroenterol, 27, pp.375~381 (2016)
125. Ge T, "Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma", Med Oncol, 32, pp.59~ (2015)
126. Shen Q, "Serum DKK1as a protein biomarker for the diagnosis of hepatocellular carcinoma : a large-scale, multicentre study", Lancet Oncol, 13, pp.817~826 (2012)
127. Fouad YM, "Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma", Scand J Gastroenterol, 51, pp.1133~1137 (2016)
128. Sakabe T, "Expression of cancer stem cell-associated DKK1 mRNA serves as prognostic marker for hepatocellular carcinoma", Anticancer Res, 37, pp.4881~4888 (2017)
129. Jang ES, "Diagnostic performance of alpha-fetoprotein, protein induced by vitamin K absence, osteopontin, dickkopf-1 and its combinations for hepatocellular carcinoma", PLoS One, 11, pp.e0151069~ (2016)
130. Liu Y, "Prognostic significance of dickkopf-1 overexpression in solid tumors : a metaanalysis", Tumour Biol, 35, pp.3145~3154 (2014)
131. Wang J, "Further study of circulating antibodies to P16, CD25 and FOXP3 in hepatocellular carcinoma", Onco Targets Ther, 12, pp.10487~10493 (2019)
132. Li Q, "The gamma-glutamyl-transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: a retrospective cohort study in China", Medicine (Baltimore), 95, pp.e3372~ (2016)
133. Nishikawa H, "Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C : a comparative study", J Viral Hepat, 23, pp.977~984 (2016)
134. Ichikawa Y, "Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection", Hepatol Res, 47, pp.226~233 (2017)
135. Park SJ, "Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma", Medicine(Baltimore), 96, pp.e5811~ (2017)
136. Balaceanu LA, "Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis", World J Clin Cases, 7, pp.1367~1382 (2019)
137. Kim JU, "Hepatocellular carcinoma : Review of disease and tumor biomarkers", World J Hepatol, 8, pp.471~484 (2016)
138. Nguyen MH, "Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis", Hepatology, 36, pp.410~417 (2002)
139. Inoue T, "Today’s new laboratory tests-How to select and use(3)", Liver disease Weekly Japan Medical News, 4771, pp.40~45 (2015)
140. Matsumoto A, "Factors associated with the effect of interferon-αsequential therapy in order to discontinue nucleoside", nucleotide analog treatment in patients with chronic hepatitis B, 2015, pp.45, 1195~1202
141. Tanaka E, "Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance", Liver Int, 26, pp.90~96 (2006)
142. Seto WK, "Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy", Am J Gastroenterol, 111, pp.1788~1795 (2016)
143. Yasunaka T, "Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis", Hepatol Int, 5, pp.918~926 (2011)

관련 논문AI추천